Comparative Pharmacology
Head-to-head clinical analysis: DECADRON versus PREDNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON versus PREDNISONE.
DECADRON vs PREDNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor and modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It also suppresses adrenal function by inhibiting ACTH secretion.
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
0.75-9 mg/day orally in divided doses every 6-12 hours; or 0.5-9 mg/day IM/IV in divided doses every 12 hours for acute conditions; for cerebral edema, IV loading dose of 10 mg followed by 4 mg IM/IV every 6 hours.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
None Documented
None Documented
Clinical Note
moderatePrednisone + Digoxin
"Prednisone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisone + Digitoxin
"Prednisone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePrednisone + Deslanoside
"Prednisone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePrednisone + Acetyldigitoxin
"Prednisone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3-4 hours (plasma); biological half-life: 36-54 hours (due to intracellular receptor binding); clinical context: duration of HPA axis suppression longer than plasma half-life
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Renal (65-80% as 17-hydroxycorticosteroids and 20-hydroxycorticosteroids after hepatic metabolism); biliary/fecal (minor, <10%)
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid